Worth Seeing!
Stock Screener - Find opportunities by screening stocks in unique ways Find Now Find Now
mw4me logo
Talk to Us | Subscribe | Advisory Services

Top Pharma Companies in India by Market Capitalisation - Identify Top Performing Pharmaceutical Sector Companies for Investment Today

Sensex 74005.94
88.91 (0.12%)

Pharma Sector Overview

Presently, India is the largest provider of generic medicines, occupying a market share of 20 percent with respect to global supply by volume and fulfils nearly 60 percent of global demand for vaccines. Indian pharmaceutical stocks even supply nearly 80 percent of antiretroviral drugs (used in combating AIDS) in the international markets.
There are several benefits of investing in pharma stocks:
  • Long-term profitability – Pharma stocks can be attractive to long-term investors in spite of the volatility. The ever rising industry size and healthcare becoming a critical part of life, investors can make good returns if they invest at the right time.
  • Exponential growth – Being the evolving industry that it is, innovation, scientific breakthroughs, and technological advances can bring in exponential growth for many pharma stocks.
×
×
Filter

Top Pharma Companies in India as on May-2024

|
 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks
Filter
Company Name
Market cap
(Rs. Cr.)
CMP
(Change %)
Latest
P/E
Latest
P/BV
5Y Sales
Gr.(%)
5Y Profit
Gr.(%)
DeciZen
More Info
1
Abbott India Ltd.
56,290
(Mid Cap)
26,617.85
(0.48%)
46.96
15.25
10.15
20.60
Unlock
2
Sanofi India Ltd.
20,399
(Small Cap)
8,820.75
(-0.42%)
35.93
18.21
0.57
9.48
Unlock
3
Neuland Laboratories Ltd.
8,025
(Small Cap)
6,228.75
(-0.42%)
26.65
6.26
17.70
56.85
Unlock
4
Apollo Hospitals Enterprise Ltd.
85,581
(Large Cap)
5,955.60
(0.06%)
85.41
11.29
-1.90
34.75
Unlock
5
Dr. Reddys Laboratories Ltd.
96,742
(Large Cap)
5,812.50
(0.23%)
17.47
3.45
11.55
36.08
Unlock
6
Astrazeneca Pharma India Ltd.
14,394
(Small Cap)
5,757.35
(-0.01%)
101.21
21.02
11.93
36.87
Unlock
7
Alkem Laboratories Ltd.
65,046
(Mid Cap)
5,421.75
(-0.34%)
37.91
5.97
11.39
9.10
Unlock
8
Procter & Gamble Health Ltd.
7,948
(Small Cap)
4,815.05
(0.56%)
36.95
9.28
11.99
36.80
Unlock
9
Pfizer Ltd.
20,146
(Small Cap)
4,438.10
(0.78%)
39.5
5.83
4.26
11.01
Unlock
10
Kovai Medical Center & Hospital Ltd.
4,414
(Small Cap)
4,062
(0.69%)
27.84
5.28
11.48
15.15
Unlock
11
Divis Laboratories Ltd.
1,03,849
(Large Cap)
3,918.75
(0.18%)
75.45
8.01
14.82
15.00
Unlock
12
Torrent Pharmaceuticals Ltd.
91,321
(Large Cap)
2,698.70
(0.02%)
61.25
12.8
10.09
20.94
Unlock
13
Dr. Lal Pathlabs Ltd.
21,282
(Small Cap)
2,532.85
(-0.65%)
54.71
11.07
11.55
11.64
Unlock
14
Ajanta Pharma Ltd.
29,965
(Mid Cap)
2,391.85
(0.51%)
37
8.46
11.98
4.54
Unlock
15
Glaxosmithkline Pharmaceuticals Ltd.
38,820
(Mid Cap)
2,358.10
(2.90%)
64.82
21.63
2.52
11.21
Unlock
16
NGL Fine-Chem Ltd.
1,451
(Small Cap)
2,336.35
(-0.54%)
40.09
5.76
19.33
11.86
Unlock
17
Mankind Pharma Ltd.
83,873
(Large Cap)
2,114.90
(1.02%)
45.97
8.71
15.71
13.53
Unlock
18
Krishna Institute of Medical Sciences Ltd
15,141
(Small Cap)
1,955.75
(3.37%)
58.95
8.49
12.50
0.00
Unlock
19
Metropolis Healthcare Ltd.
9,439
(Small Cap)
1,846.80
(0.23%)
76.68
8.91
12.15
6.00
Unlock
20
JB Chemicals & Pharmaceuticals Ltd.
28,306
(Small Cap)
1,835
(0.61%)
56.18
10.11
18.11
31.92
Unlock
21
Gland Pharma Ltd.
29,512
(Mid Cap)
1,768.35
(-1.31%)
36.6
3.38
17.42
19.02
Unlock
22
Hester Biosciences Ltd.
1,509
(Small Cap)
1,762.15
(-0.68%)
56
4.86
13.51
0.65
Unlock
23
Lupin Ltd.
75,313
(Mid Cap)
1,661.90
(0.57%)
39.56
5.3
1.04
9.19
Unlock
24
Poly Medicure Ltd.
15,745
(Small Cap)
1,649.15
(0.52%)
66.5
11.45
16.00
20.25
Unlock
25
Sun Pharmaceutical Industries Ltd.
3,67,470
(Large Cap)
1,532.85
(0.08%)
41.39
5.91
10.69
26.54
Unlock
26
RPG Life Sciences Ltd.
2,503
(Small Cap)
1,501.40
(-0.80%)
28.29
6.62
8.32
38.58
Unlock
27
Concord Biotech Ltd.
14,976
(Small Cap)
1,493.90
(4.36%)
63.6
10.69
0.00
0.00
Unlock
28
Global Health Ltd.
38,124
(Mid Cap)
1,409.10
(-0.76%)
106.93
13.56
7.84
44.84
Unlock
29
Cipla Ltd.
1,12,990
(Large Cap)
1,403.90
(0.33%)
27.82
4.29
8.47
14.67
Unlock
30
Rainbow Childrens Medicare Ltd.
13,604
(Small Cap)
1,389
(3.64%)
62.1
11.12
22.62
38.74
Unlock
Prev 1

Want to pick best stocks Undervalued Pharma Stocks for High returns?

Check Now!
Screens:
AlphaCases All-Weather Stocks 5 Star Rated Stocks Best Nifty 50 Stocks Best Nifty Next 50 Stocks Best Nifty 500 Stocks Best SmallCap Stocks Dividend Opp. Stocks Nifty Financial Services Stocks
×
×

Pharma - Today's Top Gainers

Company Name CMP Price Change(%)
Sigachi Industries
69.115%
Zydus Lifesciences
1,104.455%
Concord Biotech
1,493.904.36%
RainbowChildrenS Med
1,3893.64%
Aurobindo Pharma
1,203.903.44%
View More

Pharma - Today's Top Losers

Company Name CMP Price Change(%)
Shilpa Medicare
499.30-4.38%
Caplin Point Lab
1,313.05-1.90%
HealthcareGlobal
359.15-1.41%
Marksans Pharma
166.90-1.33%
Gland Pharma
1,768.35-1.31%
View More

News about Top Pharma Companies in India

Global Health informs about investor presentation

Global Health has informed that it enclosed the copy of Investor Presentation, for the Quarter and Financial Year ended March 31, 2024 Results of the Company.

The above information is a part of company’s filings submitted to BSE.

18 May, 2024

Saudi Food and Drug Authority completes inspection at Concord Biotech’s manufacturing unit II

In February 2024, Ministry of Health Pharmacy and Poisons Board, Republic of Kenya had completed inspection at Concord Biotech’s Unit II
17 May, 2024

Global Health - Quaterly Results

A fair growth of 14.32% in the revenue at Rs. 5786.45 millions was reported in the March 2024 quarter as compared to Rs. 5061.58 millions during year-ago period.Profit saw a slight increase of 13.93%to Rs. 922.36  millions from Rs. 809.55 millions.Operating profit surged to 1547.66 millions from the corresponding previous quarter of 1309.27 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 5786.45 5061.58 14.32 22800.08 19735.37 15.53 22800.08 19735.37 15.53
Other Income 325.47 248.54 30.95 1028.68 475.92 116.15 1028.68 475.92 116.15
PBIDT 1547.66 1309.27 18.21 6002.18 4639.56 29.37 6002.18 4639.56 29.37
Interest 62.11 63.79 -2.63 244.57 261.61 -6.51 244.57 261.61 -6.51
PBDT 1485.55 1245.48 19.28 5757.61 4377.95 31.51 5757.61 4377.95 31.51
Depreciation 233.90 203.54 14.92 870.90 860.88 1.16 870.90 860.88 1.16
PBT 1251.65 1041.94 20.13 4886.71 3517.07 38.94 4886.71 3517.07 38.94
TAX 329.29 232.39 41.70 1277.80 884.60 44.45 1277.80 884.60 44.45
Deferred Tax -12.97 9.49 -236.67 -117.95 -89.02 32.50 -117.95 -89.02 32.50
PAT 922.36 809.55 13.93 3608.91 2632.47 37.09 3608.91 2632.47 37.09
Equity 537.01 536.39 0.12 537.01 536.39 0.12 537.01 536.39 0.12
PBIDTM(%) 26.75 25.87 3.40 26.33 23.51 11.98 26.33 23.51 11.98
17 May, 2024

Poly Medicure - Quaterly Results

The Revenue for the quarter ended  March 2024 of Rs. 3609.28 millions grew by 23.05 % from Rs. 2933.12 millions.Net profit stood at Rs. 705.32  millions  compared to Rs. 574.83 millions in the corresponding previous quarter,high by 22.70%.Operating profit surged to 1130.64 millions from the corresponding previous quarter of 903.30 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 3609.28 2933.12 23.05 13072.49 10680.45 22.40 13072.49 10680.45 22.40
Other Income 156.59 86.56 80.90 581.77 362.87 60.32 581.77 362.87 60.32
PBIDT 1130.64 903.30 25.17 4076.87 3007.64 35.55 4076.87 3007.64 35.55
Interest 29.34 22.15 32.46 107.41 83.01 29.39 107.41 83.01 29.39
PBDT 1101.30 881.15 24.98 3969.46 2924.63 35.73 3969.46 2924.63 35.73
Depreciation 161.58 147.13 9.82 620.52 556.37 11.53 620.52 556.37 11.53
PBT 939.72 734.02 28.02 3348.94 2368.26 41.41 3348.94 2368.26 41.41
TAX 234.40 159.19 47.25 831.70 577.82 43.94 831.70 577.82 43.94
Deferred Tax 38.60 -21.89 -276.34 89.84 -10.98 -918.21 89.84 -10.98 -918.21
PAT 705.32 574.83 22.70 2517.24 1790.44 40.59 2517.24 1790.44 40.59
Equity 479.86 479.72 0.03 479.86 479.72 0.03 479.86 479.72 0.03
PBIDTM(%) 31.33 30.80 1.72 31.19 28.16 10.75 31.19 28.16 10.75
17 May, 2024

Glaxosmithkline Phar - Quaterly Results

The revenue zoomed 16.46% to Rs. 9108.70 millions for the quarter ended March 2024 as compared to Rs. 7821.60 millions during the corresponding quarter last year.A good growth in profit of 46.85% reported to Rs. 1930.80  millions over Rs. 1314.80 millions of corresponding previous quarter.OP of the company witnessed a marginal growth to 2851.80 millions from 1947.30 millions in the same quarter last year.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 9108.70 7821.60 16.46 34072.50 32163.40 5.94 34072.50 32163.40 5.94
Other Income 298.70 279.70 6.79 1234.80 1015.20 21.63 1234.80 1015.20 21.63
PBIDT 2851.80 1947.30 46.45 10241.30 9009.30 13.67 10241.30 9009.30 13.67
Interest 7.70 6.50 18.46 18.00 18.10 -0.55 18.00 18.10 -0.55
PBDT 2868.10 2044.80 40.26 8787.20 8981.50 -2.16 8787.20 8981.50 -2.16
Depreciation 181.00 171.80 5.36 696.80 657.70 5.94 696.80 657.70 5.94
PBT 2687.10 1873.00 43.47 8090.40 8323.80 -2.80 8090.40 8323.80 -2.80
TAX 756.30 558.20 35.49 2243.50 2276.80 -1.46 2243.50 2276.80 -1.46
Deferred Tax 144.70 -7.60 -2003.95 -113.60 -183.70 -38.16 -113.60 -183.70 -38.16
PAT 1930.80 1314.80 46.85 5846.90 6047.00 -3.31 5846.90 6047.00 -3.31
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 31.31 24.90 25.76 30.06 28.01 7.31 30.06 28.01 7.31
17 May, 2024

Krishna Institute of Medical Sciences informs about newspaper publication

Pursuant to the provisions of Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Krishna Institute of Medical Sciences has informed that it enclosed a copy of the newspaper publication on the audited (Standalone and Consolidated) financial results of the company for the quarter and financial year ended 31st March 2024 published on 17th May 2024 in Financial Express (English) and Navatelangana (Telugu). The said publication may also be accessed on the website of the company: https://www.kimshospitals.com/investors/Disclosures under Regulation 46 of SEBI (LODR) Regulations, 2015/ Newspaper advertisements.

The above information is a part of company’s filings submitted to BSE.

17 May, 2024

Track Now: 5 Star Companies, Large Cap Companies, Mid Cap Companies, Small Cap Companies, Nifty Microcap Companies, Top IT Companies, Tax saver funds, Analyze your Equity Funds, Nifty Index Funds

Trending on MoneyWorks4Me: Stock Reasearch Reports, How many stocks to own in portfolio?, Why PE Ratio is important?, How to Choose Good Stocks?, Types of Mutual Funds, Why funds future upside is more useful than past performance?

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2024.
Rank Company Market Capitalization 2024 (INR  crores)
1 Abbott India Ltd. 56,290 Crore
2 Sanofi India Ltd. 20,399 Crore
3 Neuland Laboratories Ltd. 8,025 Crore
4 Apollo Hospitals Enterprise Ltd. 85,581 Crore
5 Dr. Reddys Laboratories Ltd. 96,742 Crore
6 Astrazeneca Pharma India Ltd. 14,394 Crore
7 Alkem Laboratories Ltd. 65,046 Crore
8 Procter & Gamble Health Ltd. 7,948 Crore
9 Pfizer Ltd. 20,146 Crore
10 Kovai Medical Center & Hospital Ltd. 4,414 Crore
Find best pharma stocks to buy now
Do you know?
Asking 3 Right Questions minimizes the
RISK of Stock Investing
To Know
Right Stock | Right Price | Right Allocation
Find best stocks to buy now

Top Pharma Companies FAQs Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) P/E P/BV EV/EBITDA ROE
Sanofi India Ltd. (S) Very Good 8,821 20,399 37.13 18.82 23.83 51.69
Abbott India Ltd. (M) Very Good 26,618 56,290 46.86 15.22 31.83 31.69
Laurus Labs Ltd. (S) Very Good 443.6 23,712 147.7 5.77 32.44 21.71
Dr. Reddys Laboratories Ltd. (L) Very Good 5,813 96,742 17.34 3.42 10.95 20.88
Torrent Pharmaceuticals Ltd. (L) Very Good 2,699 91,321 61.13 12.77 29.30 20.23

Based on the past year's gain, the best performing stocks are:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) Yearly gain (%)
Lupin Ltd. (M) Somewhat Good 1,662 75,313 111.5
Zydus Lifesciences Ltd. (L) Very Good 1,104 1,05,846 102.6
Ipca Laboratories Ltd. (M) Very Good 1,311 33,049 90.39
Aurobindo Pharma Ltd. (M) Very Good 1,204 68,194 87.84
JB Chemicals & Pharmaceuticals Ltd. (S) Very Good 1,835 28,306 85.03
View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) P/E P/BV EV/EBITDA 5Y Sales Growth (%)
Laurus Labs Ltd. (S) Very Good 443.6 23,712 147.7 5.77 32.44 24.05
Granules India Ltd. (S) Somewhat Good 405.5 9,738 22.34 3.13 13.09 19.01
JB Chemicals & Pharmaceuticals Ltd. (S) Very Good 1,835 28,306 55.92 10.07 33.04 18.11
Gland Pharma Ltd. (M) Very Good 1,768 29,512 36.84 3.40 21.00 17.42
Mankind Pharma Ltd. (L) Very Good 2,115 83,873 46.00 8.71 32.07 15.71

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name Is it a Right Stock ? CMP Market Cap(Cr.) P/E P/BV EV/EBITDA 5Y Profit Growth (%)
Laurus Labs Ltd. (S) Very Good 443.6 23,712 147.7 5.77 32.44 38.61
Dr. Reddys Laboratories Ltd. (L) Very Good 5,813 96,742 17.34 3.42 10.95 36.08
JB Chemicals & Pharmaceuticals Ltd. (S) Very Good 1,835 28,306 55.92 10.07 33.04 31.92
Biocon Ltd. (M) Somewhat Good 304.9 36,720 307.8 3.37 83.77 31.80
Granules India Ltd. (S) Somewhat Good 405.5 9,738 22.34 3.13 13.09 31.51
To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now
Compliance Officer:
Name: Shrikant Jagtap
Email : shrikant.jagtap@moneyworks4me.com
Mobile No: +91 97638 00745
Grievance officer:
Name: Mukta Vaze
Email : mukta.vaze@moneyworks4me.com
Mobile No:+91 98609 19463
Principal Officer:
Name: Atharva Bhide
Email : atharva.bhide@moneyworks4me.com
Mobile No:+91 91758 99463
Sitemap play-store Download APP play-store Download APP
linkedin facebook twitter youtube insta telegram
Address: MoneyWorks4Me Investment Advisers, B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Complaints: Register a Complaint | Complaint status | Cancellation and Refund Policy | PML Act | Grievance Redressal Process | Investor charter | Terms & Conditions | Disclaimer | Disclosure
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.